6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: A new potent and selective triple reuptake inhibitor

Journal of Medicinal Chemistry

Volumn 53, Issue 13, 2010, Pages 4989-5001

  Micheli, Fabrizio ^a   Cavanni, Paolo ^a   Andreotti, Daniele ^a   Arban, Roberto ^a   Benedetti, Roberto ^a   Bertani, Barbara ^a   Bettati, Michela ^a   Bettelini, Letizia ^a   Bonanomi, Giorgio ^a   Braggio, Simone ^a   Carletti, Renzo ^a   Checchia, Anna ^a   Corsi, Mauro ^a   Fazzolari, Elettra ^a   Fontana, Stefano ^a   Marchioro, Carla ^a   Merlo Pich, Emilio ^a   Negri, Michele ^a   Oliosi, Beatrice ^a   Ratti, Emiliangelo ^a   Read, Kevin D ^c   Roscic, Maja ^b   Sartori, Ilaria ^a   Spada, Simone ^a   Tedesco, Giovanna ^a   Tarsi, Luca ^a   Terreni, Silvia ^a   Visentini, Filippo ^a   Zocchi, Alessandro ^a   Zonzini, Laura ^a   Di Fabio, Romano ^a   more..

^a GSK   (Italy)

^b GLAXOSMITHKLINE   (United Kingdom)

^c UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 (1,1 DIMETHYLETHYL) 3 METHYL 4 (3,4 DICHLOROPHENYL) 5,6 DIHYDRO 1,3(2H) PYRIDINEDICARBOXYLIC ACID; 1 (1,1 DIMETHYLETHYL) 3 METHYL 4 [[(TRIFLUOROMETHYL)SULFONYL]OXY] 5,6 DIHYDRO 1,3(2H) PYRIDINEDICARBOXYLIC ACID; 1 (1,1 DIMETHYLETHYL) 3 METHYL 4 HYDROXY 5,6 DIHYDRO 1,3(2H) PYRIDINEDICARBOXYLIC ACID; 1 (3,4 DICHLOROPHENYL) 3 AZABICYCLO[3.1.0]HEXANE; 1 [(METHYLOXY)]METHYL] 6 [4 [(TRIFLUOROMETHYL)OXY]PHENYL] 3 AZABICYCLO[4.1.0]HEPTANE; 1 [(METHYLOXY)METHYL] 6 (2 NAPHTHALENYL) 3 AZABICYCLO[4.1.0]HEPTANE; 1 [1 (4 CHLOROPHENYL)CYCLOBUTYL] 3 METHYLBUTANAMINE; 1,1 DIMETHYLETHYL 4 (3,4 DICHLOROPHENYL) 5 (HYDROXYMETHYL) 3,6 DIHYDRO 1(2H) PYRIDINEDICARBOXYLIC ACID; 1,1 DIMETHYLETHYL 4 [[(TRIFLUOROMETHYL)SULFONYL]OXY] 3,6 DIHYDRO 1(2H) PYRIDINECARBOXYLIC ACID; 3 (1,1 DIMETHYLETHYL) 7 ETHYL 6 (3,4 DICHLOROPHENYL) 3 AZABICYCLO[4.1.0]HEPTANE 3,7 DICARBOXYLIC ACID; 6 (3 CHLORO 4 FLUOROPHENYL) 1 [(METHYLOXY)METHYL] 3 AZABICYCLO[4.1.0]HEPTANE; 6 (3,4 DICHLOROPHENYL) 1 [(ETHYLOXY)METHYL] 3 AZABICYCLO[4.1.0]HEPTANE; 6 (3,4 DICHLOROPHENYL) 1 [(METHYLOXY)METHYL] 3 AZABICYCLO[4.1.0]HEPTANE; 6 (3,4 DICHLOROPHENYL) 1 [(METHYLOXY)METHYL] 3 AZABICYCLO[4.1.0]HEPTANE 3 CARBOXYLIC ACID; 6 (3,4 DICHLOROPHENYL) 1 [[(2,2,2 TRIFLUOROETHYL)OXY]METHYL] 3 AZABICYCLO[4.1.0]HEPTANE; 6 (3,4 DICHLOROPHENYL) 4 METHYL 1 [(METHYLOXY)METHYL] 3 AZABICYCLO[4.1.0]HEPTANE; 6 (3,4 DICHLOROPHENYL) 7 [(METHYLOXY)METHYL] 3 AZABICYCLO[4.1.0]HEPTANE; 6 (4 CHLOROPHENYL) 1 [(METHYLOXY)METHYL] 3 AZABICYCLO[4.1.0]HEPTANE; 6 [3 CHLORO 4 (TRIFLUOROMETHYL)PHENYL] 1 [(METHYLOXY)METHYL]3 AZABICYCLO[4.1.0]HEPTANE; 6 [4 CHLORO 3 (TRIFLUOROMETHYL)PHENYL] 1 [(METHYLOXY)METHYL] 3 AZABICYCLO[4.1.0]HEPTANE; AMFEBUTAMONE; DOPAMINE TRANSPORTER; INDATRALINE; NORADRENALIN TRANSPORTER; PAROXETINE; REBOXETINE; SEROTONIN TRANSPORTER; TRIPLE REUPTAKE INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VENLAFAXINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG POTENCY; IN VITRO STUDY; MICRODIALYSIS; MOUSE; NONHUMAN; PHARMACOPHORE; RAT;

ANIMALS; ANTIDEPRESSIVE AGENTS; AZABICYCLO COMPOUNDS; BRAIN; DEPRESSIVE DISORDER; DOPAMINE; HEPTANES; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MASS SPECTROMETRY; MICE; MICRODIALYSIS; MODELS, MOLECULAR; NEUROTRANSMITTER UPTAKE INHIBITORS; NOREPINEPHRINE; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77954347463     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm100481d     Document Type: Article

References (22)

1. Kulkarni, S. K.; Dhir, A. Current investigational drugs for major depression Expert Opin. Invest. Drugs 2009, 18, 767-788
2. Wong, M. L.; Licinio, J. From monoamines to genomic targets: a paradigm shift for drug discovery in depression Nat. Rev. Drug Discovery 2004, 3, 136-151
3. Millan, M. J. The role of monoamines in the actions of established and "novel" antidepressant agents: a critical review Eur. J. Pharmacol. 2004, 500, 371-384
4. Nemeroff, C. B. The burden of severe depression: a review of diagnostic challenges and treatment alternatives J. Psychiatr. Res. 2007, 41, 189-206
5. Arnt, J.; Christensen, A. V.; Hyttel, J. Pharmacology in vivo of the phenylindan derivative, Lu-19,005, a new potent inhibitor of dopamine, noradrenaline and 5-hydroxytryptamine uptake in rat brain Arch. Pharmacol. 1985, 329, 101-107
6. Chen, Z.; Skolnick, P. Triple uptake inhibitors: therapeutic potential in depression and beyond Expert Opin. Invest. Drugs 2007, 16, 1365-1377
7. Rakofsky, J. J.; Holtzheimer, P. E.; Nemeroff, C. B. Emerging targets for antidepressant therapies Curr. Opin. Chem. Biol. 2009, 13, 291-302
8. Liang, Y.; Shaw, A. M.; Boules, M.; Briody, S.; Robinson, J.; Oliveros, A.; Blazar, E.; Williams, K.; Zhang, Y.; Carlier, P. R. Antidepressant like pharmacological profile of a novel triple reuptake inhibitor, (1 S,2 S)-3-(methylamino)-2-(naphthalen-2-yl)-1-phenylpropan-1-ol (PRC200-SS) J. Pharmacol. Exp. Ther. 2008, 327, 573-583
9. Skolnick, P.; Popik, P.; Janowsky, A.; Beer, B.; Lippa, A. S. "Broad spectrum" antidepressants: is more better for the treatment of depression? Life Sci. 2003, 73, 3175-3179
10. Aluisio, L.; Lord, B.; Barbier, A. J.; Fraser, I. C.; Wilson, S. J.; Boggs, J.; Dvorak, L. K.; Letavic, M. A.; Maryanoff, B. E.; Carruthers, N. I. In-vitro and in-vivo characterization of JNJ-7925476, a novel triple monoamine uptake inhibitor Eur. J. Pharmacol. 2008, 587, 141-146
11. Bannwart, L. M.; Carter, D. S.; Cai, H. Y.; Choy, J. C.; Greenhouse, R.; Jaime-Figueroa, S.; Iyer, P. S.; Lin, C. J.; Lee, E. K.; Lucas, M. C. Novel 3,3-disubstituted pyrrolidines as selective triple serotonin/norepinephrine/ dopamine reuptake inhibitors Bioorg. Med. Chem. Lett. 2008, 18, 6062-6066
12. Papakostas, G. I. Dopaminergic-based pharmacotherapies for depression Eur. Neuropsychopharmacol. 2006, 16, 391-402
13. Skolnick, P.; Popik, P.; Janowsky, A.; Beer, B.; Lippa, A. S. Antidepressant-like actions of DOV21,947: a "triple" reuptake inhibitor Eur. J. Pharmacol. 2003, 461, 99-104
14. Micheli, F.; Cavanni, P.; Arban, R.; Benedetti, R.; Bertani, B.; Bettati, M.; Bettelini, L.; Bonanomi, G.; Braggio, S.; Checchia, A.; Davalli, S.; Di Fabio, R.; Fazzolari, E.; Fontana, S.; Marchioro, C.; Minick, D.; Negri, M.; Oliosi, B.; Read, K. D.; Sartori, I.; Tedesco, G.; Tarsi, L.; Terreni, S.; Visentini, F.; Zocchi, A.; Zonzini, L. 1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3. 1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors J. Med. Chem. 2010, 53, 2534-2551
15. Bettati, M.; Cavanni, P.; Di Fabio, R.; Oliosi, B.; Perini, O.; Scheid, G.; Tedesco, G.; Zonzini, L.; Micheli, F. Oxa-azaspiro derivatives: a novel class of triple re-uptake inhibitors ChemMedChem 2010, 5, 361-366
16. Mamane, V.; Gress, T.; Krause, H.; Fuerstner, A. Platinum- and gold-catalyzed cycloisomerization reactions of hydroxylated enynes J. Am. Chem. Soc. 2004, 126, 8654-8655
17. Bertani, B.; Di Fabio, R.; Micheli, F.; Tedesco, G.; Terreni, S. Preparation of Aza-Bicyclic Compounds as Inhibitors of Mono-Amines Re-Uptake and Antidepressant Agents. WO2008031772, 2008.
18. Di Fabio, R.; Micheli, F.; Tedesco, G.; Terreni, S. Preparation of 3-Azabicyclo[4.1.0]heptanes as Therapeutic Monoamine Reuptake Inhibitors. WO2008031771, 2008.
19. Cerep: Le Bois lEvẽque, 86600 Celle lEvescault, France. www.cerep.fr.
20. All the studies involving animals were carried out in accordance with European Directive 86/609/EEC governing animal welfare and protection, which is acknowledged by Italian Legislative Decree No. 116, January 27, 1992, and according to an internal review performed by the GlaxoSmithKline Committee on Animal Research and Ethics (CARE) and to the Company Policy on the Care and Use of Laboratory Animals.
21. Burchall, C. J.; Soroko, F. E.; Rigdon, G. C. Potentiation of the behavioral effects of 5-hydroxytryptophan by BW 1370U87, a selective monoamine oxidase-A inhibitor Drug Dev. Res. 1992, 25, 209-213
22. Bourin, M.; Chenu, F.; Prica, C.; Hascoet, M. Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice Psychopharmacology (Heidelberg, Germany) 2009, 206, 97-107